

**510(k) Premarket Notification**  
**510(k) Summary**

**I. GENERAL INFORMATION**

K072955(P,1,2A2)

Applicant's Name and Address: Smiths Medical MD, Inc.  
1265 Grey Fox Road  
St. Paul, MN 55112

Contact Person: David H. Short  
Director Regulatory Affairs and Design  
Assurance

Common/Usual Name: Pump Communications System

Proprietary Name: CADD-Sentry *Pro*<sup>TM</sup> Medication Safety Software

Classification Name: 21 CFR 880.5725, Accessories, Pump, Infusion

Product Code MRZ

Equivalence Device Comparison: CADD-Sentry *Pro*<sup>TM</sup> Medication Safety Software

Date Prepared February 7, 2008

FEB 13 2008

**II. DEVICE DESCRIPTION**

**CADD-Sentry *Pro*<sup>TM</sup> Medication Safety Software**

The Smiths Medical MD, Inc. CADD-Sentry *Pro*<sup>TM</sup> Medication Safety Software, a software program that operates on commercially available personal computers or similar hardware platforms such as tablets, is designed for pump programming of the CADD-Prizm<sup>®</sup> PCS II Ambulatory Infusion Pump (software revision H or higher) through a therapy-based protocol database defined by the user. The CADD-Sentry *Pro*<sup>TM</sup> Medication Safety Software consists of an Administrator and a Point-of-Care (POC) software module that employs serial communications to send and receive pump information. Both modules are compatible with barcode scanners (or similar input devices) through various PC connections. Barcode format is determined by the user; but is limited to 20 alphanumeric characters. The CADD-Sentry *Pro*<sup>TM</sup> Medication Safety Software does not allow duplicative Drug, Protocol or User identification entries.

The CADD-Sentry *Pro*<sup>TM</sup> Medication Safety Software – Administrator module allows the user to create and save therapy-based protocols, including pump settings. The Administrator module allows therapy-based protocols to be stored and edited within user-defined protocol libraries. The Administrator user determines POC user access and editing capabilities of these libraries. Other Administrator module features include barcode printing, reports, and sending and receiving pump identification.

## 510(k) Premarket Notification

### 510(k) Summary

K472955 (P.20A3)

The CADD-Sentry *Pro*<sup>™</sup> Medication Safety Software – Point-of-Care module allows the user to send and receive pump settings via serial communication sourced from protocol libraries established using the Administrator module. Additional features include storing and printing pump programs and reports, verifying pump settings to established protocols and viewing history logs in the easier view of the PC monitor.

### III. INTENDED USE OF THE DEVICE

#### CADD-Sentry *Pro*<sup>™</sup> Medication Safety Software

The CADD-Sentry *Pro*<sup>™</sup> Medication Safety Software – Administrator allows you to establish a therapy-based protocol library that will be used by the CADD-Sentry *Pro*<sup>™</sup> Medication Safety Software – Point of Care to program the CADD-Prizm<sup>®</sup> PCS II Ambulatory Infusion Pump (software revision H or higher).

The CADD-Sentry *Pro*<sup>™</sup> Medication Safety Software – Point of Care allows use of a personal computer to send CADD-Sentry *Pro*<sup>™</sup> Medication Safety Software – Administrator established therapy-based protocols to the CADD-Prizm<sup>®</sup> PCS II Ambulatory Infusion Pump (software revision H or higher).

### IV. DEVICE COMPARISON

#### CADD-Sentry *Pro*<sup>™</sup> Medication Safety Software

The CADD-Sentry *Pro*<sup>™</sup> Medication Safety Software was compared to and found to be substantially equivalent to the following commercially available predicate device: CADD-Sentry *Pro*<sup>™</sup> Medication Safety Software with respect to indications for use and performance features.

### V. SUMMARY OF STUDIES

#### **A. Functional Testing**

Test plans associated with software validation, verification of software controlled programming functions, and software related to proper software and pump operation were performed.

#### **B. Clinical Studies**

Human clinical studies were deemed not necessary to evaluate the safety or effectiveness of the CADD-Sentry *Pro*<sup>™</sup> Medication Safety Software.

#### **C. Conclusions Drawn from the Studies**

Based upon the information provided, the CADD-Sentry *Pro*<sup>™</sup> Medication Safety Software is safe, effective and performs to established specifications.



FEB 13 2008

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Mr. David H. Short  
Director Regulatory Affairs and Design Assurance  
Smiths Medical MD, Incorporated  
1265 Grey Fox Road  
St. Paul, Minnesota 55112

Re: K072955

Trade/Device Name: CADD-Sentry Pro™ Medication Safety Software – Administrator  
CADD-Sentry Pro™ Medication Safety Software – Point of Care

Regulation Number: 21 CFR 880.5725

Regulation Name: Infusion Pump

Regulatory Class: II

Product Code: MRZ

Dated: January 17, 2008

Received: January 18, 2008

Dear Mr. Short:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Chiu Lin, Ph.D.

Director

Division of Anesthesiology, General Hospital,

Infection Control and Dental Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

